Abstract
The antihypertensive properties of different doses of a chicken foot hydrolysate, Hpp11 and the mechanisms involved in this effect were investigated. Spontaneously hypertensive rats (SHR) were administered water, Captopril (50 mg/kg) or Hpp11 at different doses (25, 55 and 85 mg/kg), and the systolic blood pressure (SBP) was recorded. The SBP of normotensive Wistar-Kyoto (WKY) rats administered water or Hpp11 was also recorded. Additionally, plasmatic angiotensin-converting enzyme (ACE) activity was determined in the SHR administered Hpp11. Moreover, the relaxation caused by Hpp11 in isolated aortic rings from Sprague-Dawley rats was evaluated. Hpp11 exhibited antihypertensive activity at doses of 55 and 85 mg/kg, with maximum activity 6 h post-administration. At this time, no differences were found between these doses and Captopril. Initial SBP values of 55 and 85 mg/kg were recovered 24 or 8 h post-administration, respectively, 55 mg/kg being the most effective dose. At this dose, a reduction in the plasmatic ACE activity in the SHR was found. However, Hpp11 did not relax the aortic ring preparations. Therefore, ACE inhibition could be the mechanism underlying Hpp11 antihypertensive effect. Remarkably, Hpp11 did not modify SBP in WKY rats, showing that the decreased SBP effect is specific to the hypertensive state.
Highlights
Cardiovascular diseases (CVD) are the leading cause of mortality in Europe, and hypertension (HTN) is one of the main CVD risk factors [1]
angiotensin-converting enzyme (ACE) is the key enzyme of the renin-angiotensin-aldosterone system (RAAS), which is one of the most important systems in the regulation of blood volume and systemic vascular resistance
According to ACE inhibition, it was observed that the IC50 value
Summary
Cardiovascular diseases (CVD) are the leading cause of mortality in Europe, and hypertension (HTN) is one of the main CVD risk factors [1]. In this sense, the lowering of blood pressure (BP). One of the most popular pharmacologic therapies to treat HTN is based on the use of angiotensin-converting enzyme (ACE) inhibitors such as Captopril or Enalapril [3]. ACE is the key enzyme of the renin-angiotensin-aldosterone system (RAAS), which is one of the most important systems in the regulation of blood volume and systemic vascular resistance. Pharmacological ACE inhibitors are widely used to decrease BP, some undesirable side effects have been described for these drugs, such as angioedema, dry cough, disturbance in taste, and skin reactions, among others [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
